NCT06126276 2026-06-02Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)National Cancer Institute (NCI)Phase 2 Recruiting70 enrolled